Chinese herbal medicine firm with no revenue sends investors in frenzy, shares rise 58,000%

The Hong Kong-based firm sells traditional herbal medicine to treat ADHD and autism spectrum disorder. It is largely self-funded by Au and is still in the research and development phase read more
A small-scale Chinese herbal medicine manufacturing company was losing money until recently, when its fortunes turned overnight as its shares rose 58,000 per cent as of Monday.
The firm, named Regencell Bioscience Holding Ltd., witnessed a phenomenal revenue growth this week after its shares exploded.
The move has increased the value of Chief Executive Officer Yat-Gai Au's 86 per cent stake to $25.6 billion, according to the Bloomberg Billionaires Index, pushing Au's paper wealth above that of longtime rich-list figures like Jerry Jones and Masayoshi Son.
STORY CONTINUES BELOW THIS AD
About the company
The Hong Kong-based firm sells traditional herbal medicine to treat ADHD and autism spectrum disorder. It is largely self-funded by Au and is still in the research and development phase.
Regencell Bioscience did not turn a profit since it went public, and in fact lost $4.4 million in the fiscal year through June 30, 2024, as per its filings.
The company does not have a chief medical officer since the last person resigned in 2022.
'Both entities [Regencell and its associated foundation] are Gai's passion projects, and he will continue to invest his personal funds to defend what he believes in,' Au's bio page on the company's website says.
'He has literally put his money where his mouth is by investing over US$9 million in RGC to demonstrate his personal belief and commitment,' it added.
Founded in 2014, Regencell primarily focuses on marketing and licensing traditional remedies developed by the founder's father, Sik-Kee Au. A former security alarm business owner in California with a background in electrical engineering, the father was found guilty of professional misconduct in August 2021 by a Hong Kong practitioners' board for overprescribing medication, according to a public order.
What's behind the rally?
The rally comes amid US interest in alternative medicine and regulatory changes, but analysts warn the surge is unsustainable.
Previous speculative bubbles in similar stocks have ended in sharp corrections.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Mint

23 minutes ago

• Mint

Softbank's biggest bet: Masayoshi Son plans trillion-dollar AI hub in Arizona. Details here

SoftBank Group's founder Masayoshi Son is seeking to team up with Taiwan Semiconductor Manufacturing Co to build a trillion-dollar industrial complex in Arizona for manufacturing robots and artificial intelligence. The billionaire aims to build a version of the vast manufacturing hub in China's Shenzhen that would bring back high-tech manufacturing to the US, according to sources known to Bloomberg. The park may comprise production lines for AI-powered industrial robots. Codenamed 'Project Crystal Land', the Arizona complex represents the 67-year-old SoftBank chief's most ambitious attempt in a career that's spanned numerous bet-the-house bids, thousands-fold returns and billions of dollars in losses, said Bloomberg. SoftBank officials are expecting the Taiwanese maker of Nvidia Corp's advanced AI chips to play a prominent role in the project, although the exact plan is not clear. TSMC already plans to invest $165 billion in the US and has started mass production at its first Arizona factory. It is also not clear whether TSMC would be interested, the news report suggests. SoftBank officials have been in touch with federal and state government officials to discuss possible tax breaks for companies building factories or otherwise investing in the industrial park. Son has compiled a list of SoftBank Vision Fund portfolio companies that might take part in the Arizona manufacturing hub. SoftBank-backed startups working on robotics and automation technologies, such as Agile Robots SE may set up production facilities at the industrial complex, said the news agency. The plans' progress highly depends on support from the Trump administration and state officials. While the project may require as much as $1 trillion to execute, the actual scale depends on interest from big technology companies, the news report said. While exploring the Arizona project, Softbank also plans to invest as much as $30 billion into OpenAI. It's also seeding money into the Stargate venture with OpenAI, Oracle and Abu Dhabi's MGX, seeking to put hundreds of billions of dollars into data centres and related infrastructure around the world. Those outlays come as SoftBank's cash stood at $23 billion at the end of March. The Tokyo-based company also raised around $4.8 billion this month by selling its stake in T-Mobile US. The Softbank founder's multiple investments in projects that proceed in fits and starts make it difficult to determine how committed he is to any one venture, said the news agency The billionaire is often goaded by the desire to boost SoftBank's stock price and repay retail investors who've held onto the company's shares from before the dot-com boom and bust. Many investors have waited for decades for the stock to recover, said sources known to Bloomberg. If Son's primary motivation is to clear the way for AI, it may be more cost-efficient to encourage partnerships that link manufacturing expertise with that of AI engineers and specialists in fields from medicine to robotics, and incubating smaller companies, Melissa Otto, the head of research at Visible Alpha told Bloomberg, But pouring cash into data centres may help lower the cost of developing AI applications and spur broader adoption, she said. 'He's a long-term thinker, and he takes risks,' Otto said. 'It's just too early to tell.'

News18

30 minutes ago

• News18

Lilavati Trust Slaps Rs 1,000-Crore Defamation Suit On HDFC Bank CEO Sashidhar Jagdishan; Details Here

The Lilavati Kirtilal Mehta Medical Trust filed a Rs 1,000 crore defamation lawsuit and a criminal complaint against HDFC Bank CEO Sashidhar Jagdishan for alleged false statements. In an escalation of the ongoing dispute, the Lilavati Kirtilal Mehta Medical Trust (LKMM Trust) has filed a Rs 1,000 crore civil defamation lawsuit against HDFC Bank Managing Director & CEO Sashidhar Jagdishan, accusing him of making 'malicious, false and defamatory" statements against the Trust and its permanent trustee Prashant Mehta. In an official statement, the Trust said, 'The Lilavati Kirtilal Mehta Medical Trust (LKMM Trust) has filed a Rs 1,000 crore civil defamation lawsuit against Mr. Sashidhar Jagdishan, Managing Director & CEO of HDFC Bank, over a series of malicious, false, and defamatory statements made against the Trust and its Permanent Trustee, Mr. Prashant Mehta." The Lilavati Hospital, one of Mumbai's best-known healthcare institutions, operates under the aegis of the LKMM Trust. 'Coordinated Smear Campaign' The Trust alleged that Jagdishan launched a 'coordinated campaign to malign its reputation and obstruct its operations as a public charitable institution." In a parallel move, the Trust has also filed a criminal complaint before the Metropolitan Magistrate of Girgaon, Maharashtra. The court has issued notices to Sashidhar Jagdishan, HDFC Bank's spokesperson, and its corporate communication head. The Trust described the legal action as a vital step forward. 'The criminal complaint and subsequent notice mark a significant step in holding the HDFC CEO accountable for what the Trust alleges is a deliberate and sustained smear campaign," it said. The Trust further clarified that the legal action is not retaliatory: 'But are in response to a sustained effort to discredit a respected charitable institution and its founding family without any supporting documentation or conclusive evidence from HDFC Bank to validate its claims." FIR and Financial Fraud Allegations Denying all allegations linking it to a company under scrutiny, the Trust said, 'The Trust and Prashant Mehta are not connected to the affairs of Splendour Gems in any manner whatsoever as fraudulently espoused by the CEO of HDFC." In response, earlier this week, HDFC Bank MD and CEO Sashidhar Jagdishan approached the Bombay High Court, seeking quashing of the FIR registered against him based on the financial fraud allegations made by the Lilavati Trust, which oversees the Mumbai-based Lilavati Hospital. The plea was mentioned before the court on Wednesday and will be heard in due course of time. The FIR stems from a magistrate court's order, directing the police to investigate the charges of alleged financial fraud. The Lilavati Kirtilal Mehta Medical Trust (LKMM Trust) has alleged in the complaint that of the Rs 14.42 crore misappropriated by its trustees, Rs 2.05 crore were received by Jagdishan. It also claimed that the offer of Rs 1.5 crore disguised as Corporate Social Responsibility (CSR) funds to hospital staff shows the intent to destroy evidence and obstruct justice. Despite judicial findings and multiple complaints, HDFC Bank failed to act, violating Section 166 of the Companies Act and SEBI governance mandates, the Trust alleged. The bank, however, has denied the allegations, calling it 'outrageous and preposterous".

Time of India

31 minutes ago

• Time of India

India's forex reserves rise to $698.95 billion, up $2.29 billion as of June 13

India's forex reserves increased by $2.29 billion to $698.95 billion for the week ending June 13, data by the Reserve Bank of India showed on Friday. India's foreign exchange reserves stood at $696.66 billion as of June 6, up $5.17 billion from the previous week. The forex reserves had touched an all-time high of $704.885 billion in end-September 2024. For the week ending on June 13, foreign currency assets, a major component of the reserves, increased $1.73 billion to $589.42 billion, the data released on Friday showed. Expressed in dollar terms, the foreign currency assets include the effect of appreciation or depreciation of non-US units like the euro, pound and yen held in the foreign exchange reserves. Typically, the RBI, from time to time, intervenes in the market through liquidity management, including through the selling of dollars, with a view to preventing a steep depreciation in the rupee. Live Events The RBI closely monitors the foreign exchange markets and intervenes only to maintain orderly market conditions by containing excessive volatility in the exchange rate, without reference to any pre-determined target level or band.